Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation

Drug resistance can notably restrict clinical applications of gefitinib that is a commonly used EGFR-tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC). The attempts in exploring novel drug targets and reversal strategies are still needed, since gefitinib resistance has no...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yuhong, Zhuo, Xin, Fu, Xiujuan, Wu, Yue, Mao, Canquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100583/
https://www.ncbi.nlm.nih.gov/pubmed/33967759
http://dx.doi.org/10.3389/fphar.2021.625289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100583/
https://www.ncbi.nlm.nih.gov/pubmed/33967759
http://dx.doi.org/10.3389/fphar.2021.625289

Ejemplares similares